Tag: chRDNA

Is it Time to Dump Caribou Biosciences Inc (CRBU) Stock After it Is Lower By 12.79% in a Week?

News Home Wednesday, December 13, 2023 02:15 PM | InvestorsObserver Analysts Mentioned in this article Caribou Biosciences Inc (CRBU) stock is down 12.79% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator. Caribou Biosciences Inc has a Bearish sentiment reading. Find out what this means for…

Continue Reading Is it Time to Dump Caribou Biosciences Inc (CRBU) Stock After it Is Lower By 12.79% in a Week?

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

Caribou Biosciences, Inc. — Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT — — ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2…

Continue Reading Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

Caribou Biosciences Provides Regulatory Update on CB-010

— Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT — — ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 — —…

Continue Reading Caribou Biosciences Provides Regulatory Update on CB-010

Should You Buy Caribou Biosciences Inc (CRBU) Stock After it Is Higher By 18.73% in a Week?

News Home Thursday, November 16, 2023 01:51 PM | InvestorsObserver Analysts Mentioned in this article The market has been high on Caribou Biosciences Inc (CRBU) stock recently. CRBU gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Caribou Biosciences Inc has a Bullish sentiment reading. Find out what this means…

Continue Reading Should You Buy Caribou Biosciences Inc (CRBU) Stock After it Is Higher By 18.73% in a Week?

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

Caribou Biosciences, Inc. — Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma — BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) —  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory…

Continue Reading Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells

CRISPR-based genome editing of primary human T cells has the potential to revolutionize disease-modifying therapies. However, substantial improvements in CRISPR-Cas9 specificity are needed to minimize its off-target activity in cells. A number of “high-fidelity” Cas9 variants have been engineered in an attempt to address specificity improvements, but these proteins often…

Continue Reading Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells

AbbVie Terminates Caribou CAR-T Contract in Culling of Cancer Pipeline

Pictured: AbbVie corporate office in Illinois/iStock, vzphotos AbbVie has walked away from its collaboration and license agreement with Caribou Biosciences, the Berkeley-based biotech announced in an SEC filing posted Tuesday.   AbbVie’s decision was a strategic move by the company “and was unrelated to Caribou’s performance under the agreement or…

Continue Reading AbbVie Terminates Caribou CAR-T Contract in Culling of Cancer Pipeline

Caribou Bioscience (CRBU) Announces Termination of Collaboration and License Agreement by AbbVie (ABBV)

On September 26, 2023, Caribou Bioscience, Inc (NASDAQ: CRBU) received notice from AbbVie Manufacturing Management Unlimited Company (NASDAQ: ABBV) that AbbVie has elected to terminate the Collaboration and License Agreement, as amended, by and between the Company and AbbVie, dated February 9, 2021 (the “Agreement”). AbbVie exercised its right to…

Continue Reading Caribou Bioscience (CRBU) Announces Termination of Collaboration and License Agreement by AbbVie (ABBV)

How Can CRISPR Be Used to Treat Cancer

CRISPR Beyond Genetic Diseases When CRISPR-Cas9 was first found, and subsequently earned its discoverers a Nobel Price in 2020, the obvious first application of this technology was gene therapy. This is because CRISPR allows for very precise and targeted gene editing, making possible the idea of correcting abnormal gene sequence…

Continue Reading How Can CRISPR Be Used to Treat Cancer

Pharma Experts Discuss Gene Editing

Someone’s famous uncle once said, “With great power comes great responsibility.” Genome editing is an incredibly powerful technique with huge promise and potential for medicine, as well as many other fields including agriculture and the environment. But those wielding the power must cut through the hype, evaluate the potential, and…

Continue Reading Pharma Experts Discuss Gene Editing

Caribou Biosciences Announces $25 Million Equity Investment

— Pfizer purchases $25 million of Caribou common shares — — Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou’s Scientific Advisory Board — BERKELEY, Calif., July 06, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing…

Continue Reading Caribou Biosciences Announces $25 Million Equity Investment

What is the Market’s View on Caribou Biosciences Inc (CRBU) Stock’s Price and Volume Trends Thursday?

News Home Thursday, July 06, 2023 02:42 PM | InvestorsObserver Analysts Mentioned in this article Caribou Biosciences Inc (CRBU) stock has gained 47.77% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator. Caribou Biosciences Inc has a Neutral sentiment reading. Find out what this means for…

Continue Reading What is the Market’s View on Caribou Biosciences Inc (CRBU) Stock’s Price and Volume Trends Thursday?

Addressing the Challenges of Getting Gene and Cell Therapies to Patients

Credit: koto_feja/Getty Images Cell and gene therapy have surprisingly long histories. Cell therapy has existed in the form of bone marrow transplant, used to treat cancers and other conditions, since the late 1950’s, although it only came to prominence with the approval of the first chimeric antigen receptor (CAR) T-cell…

Continue Reading Addressing the Challenges of Getting Gene and Cell Therapies to Patients

Do Traders Think Caribou Biosciences Inc (CRBU) Can Turn Around Wednesday?

News Home Wednesday, May 24, 2023 01:32 PM | InvestorsObserver Analysts Mentioned in this article Caribou Biosciences Inc (CRBU) stock is flat 0.00% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Caribou Biosciences Inc has a Bullish sentiment reading. Find out what this means for…

Continue Reading Do Traders Think Caribou Biosciences Inc (CRBU) Can Turn Around Wednesday?

Sector to Reach $9.61 Billion by 2030 at a 14.17% CAGR

DUBLIN, May 18, 2023 /PRNewswire/ — The “Global CRISPR and Cas Genes Market, By Product & Service, By Application, By End-use By Region – Industry Trends and Forecast to 2030” report has been added to  ResearchAndMarkets.com’s offering. Research_and_Markets_Logo The CRISPR and Cas Genes market, valued at USD 3.17 billion in 2022,…

Continue Reading Sector to Reach $9.61 Billion by 2030 at a 14.17% CAGR

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board — Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development — BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today…

Continue Reading Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting | DNA RNA and Cells

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting Details Category: DNA RNA and Cells Published on Tuesday, 18 April 2023 10:14 Hits: 247 — CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML…

Continue Reading Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting | DNA RNA and Cells

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

Caribou Biosciences, Inc. — CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models — — CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for H2 2023 — BERKELEY, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a…

Continue Reading Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

Caribou gets FDA fast track for allogeneic CAR-T

Caribou Biosciences is a biopharma company that has proprietary chRDNA (CRISPR hybrid RNA-DNA) technology, which allows for the creation of genome-edited cell therapies. One of the products of this technology, CB-011, was provided Fast Track designation by the US Food and Drug Administration (FDA). The treatment candidate is being evaluated…

Continue Reading Caribou gets FDA fast track for allogeneic CAR-T

Caribou Biosciences Reports Fourth Quarter and Full Year

— CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 — — CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 — — CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 — — $317.0…

Continue Reading Caribou Biosciences Reports Fourth Quarter and Full Year

Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Caribou Biosciences, Inc. BERKELEY, Calif., March 08, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to participate in a fireside chat at the virtual Oppenheimer 33rd Annual Healthcare Conference…

Continue Reading Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

News: Cas12a chRDNA – A Novel Approach to Gene-Editing Therapy. Interview with Caribou Biosciences’ CSO Steve Kanner, Ph.D.

Steve Kanner, Ph.D. has been the Chief Scientific Officer of Caribou Biosciences since 2017, and is responsible for the company’s therapeutic discovery, research, and development activities. Steve received his undergraduate degree in Genetics from the University of California, Berkeley, and his Ph.D. in Immunology and Microbiology from the University of…

Continue Reading News: Cas12a chRDNA – A Novel Approach to Gene-Editing Therapy. Interview with Caribou Biosciences’ CSO Steve Kanner, Ph.D.

Phase 1 Trial to Test ‘Off-the-shelf’ CAR T-cell Therapy CB-011 in 2023 | CAR T-cell Therapy CB-011 to Be Tested in Hard-to-treat Myeloma in 2023

Caribou Biosciences will soon start testing its new CAR T-cell therapy candidate, CB-011, in people with relapsed or refractory multiple myeloma. A Phase 1 trial will begin enrolling eligible adults in early 2023 at multiple centers, according to the company. The announcement follows clearance of the company’s investigational new drug…

Continue Reading Phase 1 Trial to Test ‘Off-the-shelf’ CAR T-cell Therapy CB-011 in 2023 | CAR T-cell Therapy CB-011 to Be Tested in Hard-to-treat Myeloma in 2023

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences, Inc. BERKELEY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi 17th Annual BioPharma Conference, BostonPanel participation on September 8, 2022, 11:20 am ETWebcast H.C. Wainwright 24th…

Continue Reading Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences Announces – GuruFocus.com

BERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. ( CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David L. Johnson to its board of directors. Mr. Johnson is a seasoned executive with 30 years of commercial and operational experience in the biopharmaceutical…

Continue Reading Caribou Biosciences Announces – GuruFocus.com

Caribou Biosciences to Present at Upcoming Investor Conferences

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer,…

Continue Reading Caribou Biosciences to Present at Upcoming Investor Conferences

Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17th,…

Continue Reading Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at…

Continue Reading Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology

Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou’s proprietary chRDNA technology for therapeutic applications BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the publication of data…

Continue Reading Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology

Caribou Biosciences Announces Publication of Data

Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou’s proprietary chRDNA technology for therapeutic applications BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the publication of data…

Continue Reading Caribou Biosciences Announces Publication of Data

Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO | Rothwell, Figg, Ernst & Manbeck, P.C.

Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the most lucrative IPOs in gene-editing. In June 2021, Gene editing biotech Verve raised $267M in IPO proceeds and later added another $40 million after its financial underwriters opted to buy…

Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO | Rothwell, Figg, Ernst & Manbeck, P.C.